Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 39

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 39
---
 2025, Steve Forte was appointed to serve as our President and Chief Executive Officer, in addition to his current role as Chief Financial Officer, effective April 11, 2025. For more information on the arrangements we entered into with Mr. Segal and Dr. Koehler in connection with their respective departures, please see below under the headings, “Employment Arrangements with our Named Executive Officers—Segal Separation Agreement” and “—Koehler Separation Agreement.” Overview of Executive Compensation Program The board of directors and the compensation committee are responsible for establishing, implementing and continually monitoring adherence with our compensation philosophy and executive compensation programs. The board of directors and the compensation committee strive to ensure that the total compensation paid to our executive officers is fair, reasonable and competitive. Generally, the types of compensation and benefits provided to our executive officers, including the named executive officers, are similar to those provided to executive officers at comparable companies in similarly situated positions, which allows us to attract and retain talented executives. Compensation Objectives and Philosophy Our compensation programs are designed to attract and retain qualified and talented executives, motivate such executives to achieve business goals and reward them for short- and long-term performance with a simple and clear compensation structure. To achieve this objective, the compensation committee structures our executives’ compensation with a number of key elements, each with its own focus and purpose. We intend for total compensation, which we define as base salary, short-term incentive cash compensation, equity compensation and benefits to be competitive in the biopharmaceutical marketplace in which we compete for talent in order to help us achieve our short- and long-term financial and operational goals. Our board of directors reviews compensation annually for our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider the following:

| • |     | Compensation for comparable positions in the biopharmaceutical market; |

27

| • |     | Historical compensation levels of our executive officers; |

| • |     | Individual performance as compared to our expectations and objectives; and |

| • |     | Our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our shareholders and a long-term commitment to Repare. |

Setting Executive Compensation Role of the Board of Directors, the Compensation Committee and Management Our board of directors has historically determined the compensation of our executive officers, upon the recommendation of the compensation committee. The compensation committee has reviewed and recommended to the board for approval the compensation and other terms of employment of our Chief Executive